International Immunology Advance Access originally published online on July 18, 2005
International Immunology 2005 17(8):1071-1079; doi:10.1093/intimm/dxh288
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
B7.2-Ig fusion proteins enhance IL-4-dependent differentiation of tumor-sensitized CD8+ cytotoxic T lymphocyte precursors
1 Department of Oncology (C6), Graduate School of Medicine and 2 First Department of Oral and Maxillo-facial surgery, Faculty of Dentistry, Osaka University, 2-2, Yamada-oka, Suita, Osaka 565-0871, Japan
3 Department of Inflammation, Wyeth Research, Cambridge, MA 02140, USA
Correspondence to: S. Ono; E-mail: sono{at}ongene.med.osaka-u.ac.jp
The B7/CD28 co-stimulatory pathway plays a critical role in T cell activation and differentiation. Our previous study demonstrated that administration of B7.2-Ig fusion proteins to tumor-bearing mice elicits IL-4-dependent, CD8+ T cell-mediated tumor regression. Here, we investigated whether B7.2-Ig stimulation of tumor-sensitized CD8+ CTL precursors during in vitro antigen re-sensitization actually results in their differentiation into mature CTLs and if so, whether such a process depends on IL-4 signals. Splenocytes from tumor-sensitized (tumor-bearing or tumor-immunized) mice exhibited low levels of anti-tumor CTL responses upon culturing alone, but induced strikingly enhanced CTL responses when stimulated in vitro with B7.2-Ig fusion proteins. Because CTLs were not generated from normal splenocytes even by B7.2-Ig stimulation, the expression of the B7.2-Ig effect required the in vivo tumor sensitization of CD8+ CTL precursors. Administration of anti-CD4 or anti-CD40 ligand (CD40L) to mice before tumor sensitization resulted in almost complete inhibition of CTL responses generated in the subsequent culture containing B7.2-Ig. In contrast, anti-IL-4 did not influence in vivo tumor sensitization required for CTL induction. However, B7.2-Ig stimulation of tumor-sensitized splenocytes enhanced IL-4 production and neutralization of this IL-4 with anti-IL-4 potently down-regulated CTL responses. These results indicate that B7.2-Ig enhances IL-4-dependent differentiation of anti-tumor CD8+ CTL precursors that can be sensitized in vivo depending on collaboration with CD4+ T cells involving CD40L function.
Keywords: costimulation, Th1/Tc2, Th2/Tc2, tumor immunity, CD40L
Transmitting editor: A. Singer
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
K. Nagahara, T. Arikawa, S. Oomizu, K. Kontani, A. Nobumoto, H. Tateno, K. Watanabe, T. Niki, S. Katoh, M. Miyake, et al. Galectin-9 Increases Tim-3+ Dendritic Cells and CD8+ T Cells and Enhances Antitumor Immunity via Galectin-9-Tim-3 Interactions J. Immunol., December 1, 2008; 181(11): 7660 - 7669. [Abstract] [Full Text] [PDF] |
||||
